Match!
H. Bryan Brewer
MedStar Washington Hospital Center
EndocrinologyCholesterolLipoproteinBiochemistryApolipoprotein B
233Publications
68H-index
31.3kCitations
What is this?
Publications 235
Newest
#1Ron Waksman (MedStar Washington Hospital Center)H-Index: 76
#2Carlo Di Mario (UniFI: University of Florence)H-Index: 83
Last. David E. NewbyH-Index: 79
view all 50 authors...
Summary Background Near-infrared spectroscopy (NIRS) intravascular ultrasound imaging can detect lipid-rich plaques (LRPs). LRPs are associated with acute coronary syndromes or myocardial infarction, which can result in revascularisation or cardiac death. In this study, we aimed to establish the relationship between LRPs detected by NIRS-intravascular ultrasound imaging at unstented sites and subsequent coronary events from new culprit lesions. Methods In this prospective, cohort study (LRP), pa...
8 CitationsSource
BackgroundThe cholesteryl ester transfer protein inhibitor evacetrapib substantially raises the high-density lipoprotein (HDL) cholesterol level, reduces the low-density lipoprotein (LDL) cholesterol level, and enhances cellular cholesterol efflux capacity. We sought to determine the effect of evacetrapib on major adverse cardiovascular outcomes in patients with high-risk vascular disease. MethodsIn a multicenter, randomized, double-blind, placebo-controlled phase 3 trial, we enrolled 12,092 pat...
188 CitationsSource
#1Stephen J. Nicholls (University of Adelaide)H-Index: 63
#2Giacomo Ruotolo (Eli Lilly and Company)H-Index: 12
Last. Steven E. Nissen (Cleveland Clinic)H-Index: 81
view all 9 authors...
Background Potent CETP inhibitors reduce plasma concentrations of atherogenic lipoprotein biomarkers of cardiovascular risk. Objectives To evaluate the effects of the cholesteryl ester transfer protein (CETP) inhibitor evacetrapib, as monotherapy or with statins, on atherogenic apolipoprotein B (apoB)–containing lipoproteins in mildly hypercholesterolemic patients. Methods VLDL and LDL particle concentrations and sizes (using nuclear magnetic resonance spectroscopy) and lipoprotein(a) concentrat...
12 CitationsSource
#1Michael J. Lipinski (MedStar Washington Hospital Center)H-Index: 30
#2Umberto Benedetto (BRI: Bristol Royal Infirmary)H-Index: 22
Last. Ron Waksman (MedStar Washington Hospital Center)H-Index: 76
view all 9 authors...
Aims We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolaemia to compare the impact of proprotein convertase subtilisin-kexin type 9 serine protease (PCSK9) inhibitors with placebo and ezetimibe on lipid levels and outcomes. Methods and results MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing PCSK9 inhibitors vs. other therapies in patients with primary hypercholesterolaemia. Network meta-a...
140 CitationsSource
#1Stephen J. NichollsH-Index: 63
#2R. Puri Mbbs (Cleveland Clinic)H-Index: 37
Last. Steven E. Nissen (Cleveland Clinic)H-Index: 81
view all 14 authors...
Background Bromodomain and extra-terminal (BET) proteins regulate transcription of lipoprotein and inflammatory factors implicated in atherosclerosis. The impact of BET inhibition on atherosclerosis progression is unknown.
41 CitationsSource
#1Robert S. Rosenson (ISMMS: Icahn School of Medicine at Mount Sinai)H-Index: 59
#2H. Bryan Brewer (MedStar Washington Hospital Center)H-Index: 68
Last. Nancy R. Webb (UK: University of Kentucky)H-Index: 35
view all 9 authors...
High-density lipoproteins (HDLs) have various antiatherosclerotic effects; however, inflammation can cause HDL to become dysfunctional, which impairs its protective properties. In this Review, Rosenson and colleagues discuss the mechanisms by which HDL and apolipoprotein A-I protect against atherosclerosis, and how diagnostic and therapeutic approaches might target these proteins when they become dysfunctional.
196 CitationsSource
#1Stephen J. Nicholls (University of Adelaide)H-Index: 63
#2A.M. Lincoff (Cleveland Clinic)H-Index: 97
Last. Steven E. Nissen (Cleveland Clinic)H-Index: 81
view all 17 authors...
Background Potent pharmacologic inhibition of cholesteryl ester transferase protein by the investigational agent evacetrapib increases high-density lipoprotein cholesterol by 54% to 129%, reduces low-density lipoprotein cholesterol by 14% to 36%, and enhances cellular cholesterol efflux capacity. The ACCELERATE trial examines whether the addition of evacetrapib to standard medical therapy reduces the risk of cardiovascular (CV) morbidity and mortality in patients with high-risk vascular disease....
52 CitationsSource
#1Michael J. LipinskiH-Index: 30
Last. Ron WaksmanH-Index: 76
view all 7 authors...
Introduction: We performed a network meta-analysis of randomized controlled trials (RCTs) in patients with primary hypercholesterolemia to compare the impact of PCSK9 inhibitors with placebo and ezetimibe on lipid levels and outcomes. Hypothesis: PCSK9 inhibitors will significantly lower LDL-C greater than ezetimibe and improve outcomes. Methods: MEDLINE/PubMed, Cochrane CENTRAL, and ClinicalTrials.gov were searched for RCTs assessing PCSK9 inhibitors versus other therapies in patients with prim...
#1Stephen J. Nicholls (University of Adelaide)H-Index: 63
#2Giacomo Ruotolo (Eli Lilly and Company)H-Index: 12
Last. Daniel J. Rader (Cardiovascular Institute of the South)H-Index: 137
view all 9 authors...
Abstract Background Potent cholesteryl ester transfer protein (CETP) inhibitors have been shown to substantially increase high-density lipoprotein cholesterol (HDL-C) and apolipoprotein A-I levels as monotherapy and combined with statins. However, data on the effects of this class of drugs on macrophage cholesterol efflux capacity (CEC), a functional assay that characterizes a key step in the process of reverse cholesterol transport, are limited. Objectives This study assessed the impact of evac...
65 CitationsSource
#1G. Kees Hovingh (UvA: University of Amsterdam)H-Index: 53
#2John J.P. Kastelein (UvA: University of Amsterdam)H-Index: 119
Last. Philip J. Barter (UNSW: University of New South Wales)H-Index: 85
view all 9 authors...
Summary Background Dyslipidaemia remains a significant risk factor for cardiovascular disease and additional lipid-modifying treatments are warranted to further decrease the cardiovascular disease burden. We assessed the safety, tolerability and efficacy of a novel cholesterol esterase transfer protein (CETP) inhibitor TA-8995 in patients with mild dyslipidaemia. Methods In this randomised, double-blind, placebo-controlled, parallel-group phase 2 trial, we recruited patients (aged 18–75 years) f...
104 CitationsSource
12345678910